Yahoo Finance

Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg ...

HAMPTON, N.J., Nov. 05, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from the Company’s Phase 1b study of barzolvolimab in prurigo nodularis (PN).
Business Wire

Mayo Clinic and PN Medical Publish Study that Shows How to Reduce Stress and Anxiety

An 18% reduction in stress was one of the most significant outcomes. ORLANDO, Fla.--(BUSINESS WIRE)--Mayo Clinic released the results of a clinical trial demonstrating the positive outcomes of a ...
Yahoo Finance

PN Medical Launches First-of-Its-Kind Study to Show Direct Impact of Respiratory Muscle Training

Orlando, Florida--(Newsfile Corp. - October 6, 2023) - PN Medical, a cardiopulmonary device manufacturer developing combined respiratory muscle training (cRMT) devices, today announced that it has ...
Nasdaq

Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235

Protagonist Therapeutics, Inc. PTGX announced that it has dosed the first patient in a phase I study, evaluating its oral interleukin-23 receptor (IL-23R) antagonist peptide – PN-235 (also known as ...